Tags

Type your tag names separated by a space and hit enter

Lung cancer in patients with idiopathic pulmonary fibrosis.
Pulm Pharmacol Ther 2017; 45:1-10PP

Abstract

Idiopathic pulmonary fibrosis (IPF) is a chronic fibrotic lung disease of unknown etiology. With a gradually increasing worldwide prevalence and a mortality rate exceeding that of many cancers, IPF diagnosis and management are critically important and require a comprehensive multidisciplinary approach. This approach also involves assessment of comorbid conditions, such as lung cancer, that exerts a dramatic impact on disease survival. Emerging evidence suggests that progressive lung scarring in the context of IPF represents a risk factor for lung carcinogenesis. Both disease entities present with major similarities in terms of pathogenetic pathways, as well as potential causative factors, such as smoking and viral infections. Besides disease pathogenesis, anti-cancer agents, including nintedanib, have been successfully applied in the treatment of patients with IPF while an oncologic approach with a cocktail of several pleiotropic anti-fibrotic agents is currently in the therapeutic pipeline of IPF. Nevertheless, epidemiologic association between IPF and lung cancer does not prove causality. Currently there is significant lack of knowledge supporting a direct association between lung fibrosis and cancer reflecting to disappointing therapeutic algorithms. An optimal therapeutic strategy for patients with both IPF and lung cancer represents an amenable need. This review article synthesizes the current state of knowledge regarding pathogenetic commonalities between IPF and lung cancer and focuses on clinical and therapeutic data that involve both disease entities.

Authors+Show Affiliations

First Academic Department of Pneumonology, Hospital for Diseases of the Chest, "Sotiria", Medical School, National and Kapodistrian University of Athens, Athens, Greece.First Academic Department of Pneumonology, Hospital for Diseases of the Chest, "Sotiria", Medical School, National and Kapodistrian University of Athens, Athens, Greece.Pathology Department, Hospital for Diseases of the Chest,"Sotiria", Messogion Avenue 152, Athens 11527, Greece.Department of Pneumonology, Democritus University of Thrace, Greece.Division of Immunology, Biomedical Sciences Research Center "Alexander Fleming", Athens, Greece.2nd Pulmonary Medicine Department, Attikon University Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece.First Academic Department of Pneumonology, Hospital for Diseases of the Chest, "Sotiria", Medical School, National and Kapodistrian University of Athens, Athens, Greece.First Academic Department of Pneumonology, Hospital for Diseases of the Chest, "Sotiria", Medical School, National and Kapodistrian University of Athens, Athens, Greece; Division of Immunology, Biomedical Sciences Research Center "Alexander Fleming", Athens, Greece. Electronic address: argyrios.tzouvelekis@fleming.gr.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

28377145

Citation

Karampitsakos, Theodoros, et al. "Lung Cancer in Patients With Idiopathic Pulmonary Fibrosis." Pulmonary Pharmacology & Therapeutics, vol. 45, 2017, pp. 1-10.
Karampitsakos T, Tzilas V, Tringidou R, et al. Lung cancer in patients with idiopathic pulmonary fibrosis. Pulm Pharmacol Ther. 2017;45:1-10.
Karampitsakos, T., Tzilas, V., Tringidou, R., Steiropoulos, P., Aidinis, V., Papiris, S. A., ... Tzouvelekis, A. (2017). Lung cancer in patients with idiopathic pulmonary fibrosis. Pulmonary Pharmacology & Therapeutics, 45, pp. 1-10. doi:10.1016/j.pupt.2017.03.016.
Karampitsakos T, et al. Lung Cancer in Patients With Idiopathic Pulmonary Fibrosis. Pulm Pharmacol Ther. 2017;45:1-10. PubMed PMID: 28377145.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Lung cancer in patients with idiopathic pulmonary fibrosis. AU - Karampitsakos,Theodoros, AU - Tzilas,Vasilios, AU - Tringidou,Rodoula, AU - Steiropoulos,Paschalis, AU - Aidinis,Vasilis, AU - Papiris,Spyros A, AU - Bouros,Demosthenes, AU - Tzouvelekis,Argyris, Y1 - 2017/04/01/ PY - 2016/12/22/received PY - 2017/02/28/revised PY - 2017/03/31/accepted PY - 2017/4/6/pubmed PY - 2018/4/20/medline PY - 2017/4/6/entrez KW - Idiopathic pulmonary fibrosis KW - Lung cancer KW - Pathogenesis KW - Scarcinoma KW - Treatment SP - 1 EP - 10 JF - Pulmonary pharmacology & therapeutics JO - Pulm Pharmacol Ther VL - 45 N2 - Idiopathic pulmonary fibrosis (IPF) is a chronic fibrotic lung disease of unknown etiology. With a gradually increasing worldwide prevalence and a mortality rate exceeding that of many cancers, IPF diagnosis and management are critically important and require a comprehensive multidisciplinary approach. This approach also involves assessment of comorbid conditions, such as lung cancer, that exerts a dramatic impact on disease survival. Emerging evidence suggests that progressive lung scarring in the context of IPF represents a risk factor for lung carcinogenesis. Both disease entities present with major similarities in terms of pathogenetic pathways, as well as potential causative factors, such as smoking and viral infections. Besides disease pathogenesis, anti-cancer agents, including nintedanib, have been successfully applied in the treatment of patients with IPF while an oncologic approach with a cocktail of several pleiotropic anti-fibrotic agents is currently in the therapeutic pipeline of IPF. Nevertheless, epidemiologic association between IPF and lung cancer does not prove causality. Currently there is significant lack of knowledge supporting a direct association between lung fibrosis and cancer reflecting to disappointing therapeutic algorithms. An optimal therapeutic strategy for patients with both IPF and lung cancer represents an amenable need. This review article synthesizes the current state of knowledge regarding pathogenetic commonalities between IPF and lung cancer and focuses on clinical and therapeutic data that involve both disease entities. SN - 1522-9629 UR - https://www.unboundmedicine.com/medline/citation/28377145/Lung_cancer_in_patients_with_idiopathic_pulmonary_fibrosis_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1094-5539(16)30199-7 DB - PRIME DP - Unbound Medicine ER -